Inspire ends denufosol retinal program
This article was originally published in Pharmaceutical Approvals Monthly
Inspire discontinues its Phase II pilot trials of the P2Y2 agonist denufosol (INS37217) for macular edema "and has no plans to conduct any further studies of denufosol for the treatment of retinal disease," the firm says Jan. 20. Data in two studies "did not demonstrate improvement in either reduction or retinal thickness or improvement in visual acuity." While the trials have been halted, Inspire will follow treated patients for one year. The company announced Jan. 30 that it is moving denufosol into Phase III for treatment of cystic fibrosis. Inspire has another P2Y2 agent, diquafosol, which is "approvable" for dry eye (1Pharmaceutical Approvals Monthly December 2005, p. 5)...
You may also be interested in...
Pfizer’s anidulafungin received a second “approvable” letter Nov. 25 for treatment of esophageal candidiasis, FDA said.
Cosmetics Europe Talks Microplastic: ECHA Frustrations, ‘Value Judgments’ And International Trade Uncertainty
The European Chemicals Agency's microplastic restriction proposal received committee backing in 2020 without changes sought by the cosmetics industry, which faces €15bn in projected costs and scarce alternatives at present. It may come down to EU Member States to decide whether the ECHA restriction proposal is proportionate in balancing environmental goals and socio-economic impacts.
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.